GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma. Cell Signal. 2020 Jan 11;:109539 Authors: El-Arabey AA, Denizli M, Kanlikilicer P, Bayraktar R, Ivan C, Rashed M, Kabil N, Ozpolat B, Calin GA, Salama SA, Abd-Allah AR, Sood AK, Lopez-Berestein G Abstract High-grade serous ovarian carcinoma (HGSOC) is the mos...

There are 5 clinical trials for malignant ovarian serous tumor, of which 5 are open and 0 are completed or closed. Of the trials that contain malignant ovarian serous tumor as an inclusion criterion, 1 is phase 1 (1 open), 2 are phase 2 (2 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open). BRCA1 and BRCA2 are the most frequent gene inclusion criteria for malignant ovarian serous tumor clinical trials [3]. ...

The TP53 gene mutation frequency in ovarian serous carcinomas has been reported to range between 50% and 80%. A research team working at the The Sidney Kimmel Comprehensive Cancer Center of The Johns Hopkins Medical Institutions (Johns Hopkins) made several important findings regarding TP53 gene mutations with respect to high grade ovarian serous carcinoma, as reported in the International Journal of Gynecological Cancer. Ovarian serous carcinoma is the most common tumor subtype within the epithelial ovarian cancer histological classification.. According to the Johns Hopkins research team, a stringent analysis of the TP53 gene using purified epithelial tumor samples has not been performed to accurately assess the TP53 gene mutation frequency and its correlation to tumor histologic grade. The research team assessed the TP53 gene mutational profile in a relatively large series of high-grade (53 primary tumors and 18 recurrent tumors) and 13 low-grade ovarian serous tumors. All samples were ...

TY - JOUR. T1 - Gene expression analysis identifies two groups of ovarian high-grade serous carcinomas with different prognosis. AU - Espinosa, Inigo. AU - Catasus, Lluis. AU - Canet, Belén. AU - DAngelo, Emanuela. AU - Mũoz, Josefina. AU - Prat, Jaime. PY - 2011/6/1. Y1 - 2011/6/1. N2 - Gene expression profiling is an important tool to evaluate genetic heterogeneity in carcinomas and is useful to develop expression-based classifications for many types of cancer, as well as markers of disease outcome. In this study, we have investigated the expression profile of 22 genes involved in the PI3K-AKT pathway in 26 high-grade ovarian carcinomas (19 serous and 7 clear cell carcinomas). Unsupervised hierarchical clustering divided high-grade ovarian carcinomas into three groups. Although all clear cell carcinomas clustered in one group, high-grade serous carcinomas were segregated into two separate groups with different prognosis (P=0.05). High expression of CASP3, XIAP (X-linked inhibitor of ...

The TP53 mutation frequency in ovarian serous carcinomas has been reported to range between 50% and 80%, but a stringent analysis of TP53 using purified epithelial samples has not yet been performed to accurately assess the mutation frequency and to correlate it with the histologic grade. The purpose of this study was to assess the TP53 mutational profile in a relatively large series of high-grade (53 primary and 18 recurrent) and 13 low-grade ovarian serous tumors using DNA isolated from affinity-purified tumor cells and to correlate it with in vitro drug resistance. All samples were affinity purified, and the tumor DNA was analyzed for TP53 mutations in exons 4-9. In vitro drug resistance assays to carboplatin, cisplatin, paclitaxel, and taxotere were performed on the same tumor samples and correlated with the TP53 mutation status. TP53 mutations were detected in 57 (80.3%) of 71 high-grade carcinomas and in one (7.8%) of 13 low-grade serous tumors (an invasive low-grade serous carcinoma). The ...

Dishevelled family proteins (DVL1, DVL2 and DVL3) are cytoplasmic mediators involved in canonical and non-canonical Wnt signaling that are important for embryonic development. Since Wnt signaling promotes cell proliferation and invasion, its increased activation is associated with cancer development as well. To get deeper insight into the behavior of Dishevelled proteins in cancer, we studied their expression in serous ovarian carcinomas [both low- (LGSC) and high-grade (HGSC)], and HGSC cell lines OVCAR5, OVCAR8 and OVSAHO. DVL protein expression in serous ovarian carcinomas tissues was analyzed using immunohistochemistry while DVL protein and mRNA expressions in HGSC cell lines were analyzed using western blot and quantitative real-time PCR. DVL1 protein expression was significantly higher in LGSC compared with normal ovarian tissue, while DVL3 was overexpressed in both LGSC and HGSC. DVL2 and DVL3 protein expression was higher in HGSC cell lines when compared with normal control cell line ...

Uterine serous carcinoma is a rare and highly aggressive variant of endometrial cancer. Uterine serous carcinoma accounts for 10% of all endometrial cancer; however, it carries the poorest prognosis, with 5-year survival rates as low as 55%. Whole-exome sequencing studies have recently reported c-Myc gene amplification in a large ...

NAD(P)H:quinone oxidoreductase (NQO1) is a flavoprotein that catalyzes two-electron reduction and detoxification of quinones and its derivatives. NQO1 catalyzes reactions that have a protective effect against redox cycling, oxidative stress and neoplasia. High expression of NQO1 is associated with many solid tumors including those affecting the colon, breast and pancreas; however, its role in the progression of ovarian carcinoma is largely undefined. This study aimed to investigate the clinicopathological significance of high NQO1 expression in serous ovarian carcinoma. NQO1 protein expression was assessed using immunohistochemical (IHC) staining in 160 patients with serous ovarian carcinoma, 62 patients with ovarian borderline tumors and 53 patients with benign ovarian tumors. Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to detect NQO1 mRNA expression levels. The correlation between high NQO1 expression and clinicopathological features of ovarian carcinoma was evaluated by

High-grade serous ovarian cancer (HGSOC) accounts for 70-80% of ovarian cancer deaths, and overall survival has not changed significantly for several decades. In this Opinion article, we outline a set of research priorities that we believe will reduce incidence and improve outcomes for women with this disease. This roadmap for HGSOC was determined after extensive discussions at an Ovarian Cancer Action meeting in January 2015.

High-grade serous ovarian cancer (HGSOC) is the most aggressive histological type of epithelial ovarian cancer, which is characterized by a high frequency of somatic TP53 mutations. We performed exome analyses of tumors and matched normal tissues of 34 Japanese patients with HGSOC and observed a substantial number of patients without TP53 mutation (24%, 8/34). Combined with the results of copy number variation analyses, we subdivided the 34 patients with HGSOC into subtypes designated ST1 and ST2. ST1 showed intact p53 pathway and was characterized by fewer somatic mutations and copy number alterations. In contrast, the p53 pathway was impaired in ST2, which is characterized by abundant somatic mutations and copy number alterations. Gene expression profiles combined with analyses using the Gene Ontology resource indicate the involvement of specific biological processes (mitosis and DNA helicase) that are relevant to genomic stability and cancer etiology. In particular we demonstrate the presence of a

High-grade serous ovarian cancer (HGSOC) accounts for 70-80% of ovarian cancer deaths, and overall survival has not changed significantly for several decades. In this Opinion article, we outline a set of research priorities that we believe will reduce incidence and improve outcomes for women with th …

High-grade serous ovarian cancer (HGSOC) likely originates from the fallopian tube (FT) epithelium, but advanced stages are mostly found outside the FT. We used ex-vivo cultures of HGSOC and knock-out of tumor suppressors in FT organoids to study changes in epithelial cells and niche requirements for normal and transformed FT cells. We found that transformed cells require BMP signaling and are growth arrested in Wnt rich medium. A SureSelectXT Automation Custom Capture Library (Agilent) target enrichment panel was designed. The enrichment panel comprised all coding exons of 121 genes associated with ovarian cancer. Capture was performed according to the manufacturers instructions using an NGS Workstation Option B (Agilent) for automat... (Read more) ...

The effective treatment of ovarian serous carcinoma remains a major challenge because of the recurrence of platinum-resistant tumors. The mechanism of platinum-resistance may involve decreased cellular uptake caused by abnormalities of transporters, intracellular cisplatin inactivation (e.g., caused by glutathione), and increased DNA repair (18). However, no available therapy prevents platinum-resistance.. TBX2 is overexpressed by numerous human cancers (7-14). TBX2 may serve as a prognostic factor of breast cancer (7,9), melanoma (8), gastric cancer (10), prostate cancer (11), laryngeal squamous cell carcinoma (12), and non-small cell lung cancer (14). TBX2 is associated with resistance to therapeutic drugs such as cisplatin and doxorubicin (15,16), and TBX2 therefore may serve as a therapeutic target.. One report shows that chromosome 17q12-q24 harbors strong candidates for ovarian tumorigenesis, such as LASP1 (17q12), TGF11 (17q21.32), MUL (17q23.2), TBX2 (17q23.2), AXIN2 (17q24.3), and GRB2 ...

Dr. Natalie Banet moderates the discussion of studies pertinent to the practice of Gynecological Pathology, led by pathology trainees. Articles to be covered: Zarei S, et al. Clinicopathologic, Immunohistochemical, and Molecular Characteristics of Ovarian Serous Carcinoma With Mixed Morphologic Features of High-grade and Low-grade Serous Carcinoma. Am J Surg Pathol. 2020;44(3):316-328. Seidman JD, et al. Intratumoral Heterogeneity Accounts for Apparent Progression of Noninvasive Serous Tumors to Invasive Low-grade Serous Carcinoma: A Study of 30 Low-grade Serous Tumors of the Ovary…. ...

High-grade serous ovarian carcinoma (HGSOC) is a lethal disease for which improved screening and treatment strategies are urgently required. Progress in these areas has been impeded by our poor understanding of HGSOC pathogenesis. The vast majority of ovarian cancer research is been based on the hypothesis that HGSOC develops from ovarian surface epithelial cells. However, recent studies suggest that , 50% of high-grade serous carcinomas involving the ovary likely arose from secretory cells of the fallopian tube epithelium. Consequently, current ovarian-based experimental models of HGSOC are inadequate in representing the full spectrum of the disease. The aim of our study was to develop the first experimental model of fallopian tube secretory epithelial cell (FTSEC) transformation and to use this model to answer three basic questions: 1) Can FTSECs be transformed in vitro?, 2) What genetic alterations are capable of transforming FTSECs?, and 3) Do transformed FTSECs give rise to high-grade ...

Ovarian cancer accounts for 5% of all female cancer-related deaths, more than any other reproductive cancer. Of the various histological subtypes, high-grade serous carcinoma is the most common. Mutations in BRCA1/BRCA2, which are associated with familial predisposition, are present in 10% of cases, while TCGA data demonstrates that P53 is mutated in 96% of high-grade serous ovarian carcinomas. In addition to aberrant P53 expression, severe aneuploidy with a near polyploid number of chromosomes is the only other genetic abnormality associated with these tumors. Ploidy changes occur early in tumor development, suggesting that they play a crucial role in oncogenic transformation. Furthermore, severe aneuploidy is associated with poor clinical outcome in patients, presumably due to its role in treatment resistance.. We used an in vitro cell culture model derived from ovarian cystadenomas, the benign counterparts of ovarian carcinomas, to investigate the molecular events leading to such ploidy ...

Objective: The purpose of this study was to investigate the prognostic value of lymph node ratio (LNR) in patients with stage III ovarian high-grade serous carcinoma (HGSC). Methods: A multicenter, retrospective department database review was performed to identify patients with ovarian HGSC at 6 gynecologic oncology centers in Turkey. A total of 229 node-positive women with stage III ovarian HGSC who had undergone maximal or optimal cytoreductive surgery plus systematic lymphadenectomy followed by paclitaxel plus carboplatin combination chemotherapy were included. LNR, defined as the percentage of positive lymph nodes (LNs) to total nodes recovered, was stratified into 3 groups: LNR1 (,10%), LNR2 (10%,= LNR,50%), and LNR3 (,= 50%). Kaplan-Meier method was used to generate survival data. Factors predictive of outcome were analyzed using Cox proportional hazards models. Results: Thirty-one women (13.6%) were classified as stage IIIA1, 15 (6.6%) as stage IIIB, and 183 (79.9%) as stage IIIC. The ...

This review focuses on recent advances in the area of low-grade ovarian serous neoplasia with emphasis on key diagnostic criteria, differential diagnosis, and disease classification based on current understanding of low-grade serous carcinogenesis. Despite considerable controversy surrounding serous tumors of low malignant potential (S-LMP) or borderline tumors, there have been great strides in our understanding of the serous group of borderline and malignant pelvic epithelial neoplasms in the past decade. Most S-LMP have a favorable prognosis, but recurrences and progression to carcinoma occur, sometimes following a protracted clinical course. Pathologic risk factors vary, but the extraovarian implant status is the most important predictor for progressive disease. Progression of S-LMP usually takes the form of low-grade serous carcinoma, although transformation to high-grade carcinoma is occasionally seen. A pelvic S-LMP - low-grade serous carcinoma pathway has been proposed based on global gene

Study identifies cell-of-origin in the development of many ovarian tumors, including including high grade serous ovarian carcinoma (HGSOC)

High expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.

See also ; ovarian tumors Appearance : ovarian epithelial tumors ovarian serous tumors benign ovarian serous tumors proliferating (...)

Mutations in the gene encoding the p110α subunit of PI3K (PIK3CA) that result in enhanced PI3K activity are frequently observed in human cancers. To better understand the role of mutant PIK3CA in the initiation or progression of tumorigenesis, we generated mice in which a PIK3CA mutation commonly detected in human cancers (the H1047R mutation) could be conditionally knocked into the endogenous Pik3ca locus. Activation of this mutation in the mouse ovary revealed that alone, Pik3caH1047R induced premalignant hyperplasia of the ovarian surface epithelium but no tumors. Concomitantly, we analyzed several human ovarian cancers and found PIK3CA mutations coexistent with KRAS and/or PTEN mutations, raising the possibility that a secondary defect in a co-regulator of PI3K activity may be required for mutant PIK3CA to promote transformation. Consistent with this notion, we found that Pik3caH1047R mutation plus Pten deletion in the mouse ovary led to the development of ovarian serous adenocarcinomas and ...

Complex focal chromosomal rearrangements in cancer genomes, also called firestorms, can be scored from DNA copy number data. The complex arm-wise aberration index (CAAI) is a score that captures DNA copy number alterations that appear as focal complex events in tumors, and has potential prognostic value in breast cancer. This study aimed to validate this DNA-based prognostic index in breast cancer and test for the first time its potential prognostic value in ovarian cancer. Copy number alteration (CNA) data from 1950 breast carcinomas (METABRIC cohort) and 508 high-grade serous ovarian carcinomas (TCGA dataset) were analyzed. Cases were classified as CAAI positive if at least one complex focal event was scored. Complex alterations were frequently localized on chromosome 8p (n = 159), 17q (n = 176) and 11q (n = 251). CAAI events on 11q were most frequent in estrogen receptor positive (ER+) cases and on 17q in estrogen receptor negative (ER-) cases. We found only a modest correlation between ...

Low grade serous ovarian cancer affects approximately 1 in 1000 women, many will be diagnosed in their 20s and 30s. With current medical treatments ...

The Notch signaling pathway is an important cell signaling system, which regulates cell differentiation, proliferation, and apoptosis, and is aberrantly activated in a wide range of cancer, including ovarian cancers. However, it remains unclear as to whether Notch signaling plays a role in the progr …

Ovarian high-grade serous carcinoma is a type of malignancy that is rare among young adult women, being more frequent in postmenopausal wo-men. Cancer of the ovary, fallopian tube and peritoneum. Lymph Node Dissection for Ovarian Cancer gastric cancer research Leacuri detoxifiere ficat verruca foot sock, hpv e cancer de pulmao cancer femei simptome.

https://doi.org/10.18632/oncotarget.21175 Véronique DHondt, Magalie Lacroix-Triki, Marta Jarlier, Florence Boissiere-Michot, Carole Puech, Peter Coopman, Dionyssios Katsaros, Gilles Freiss

David Bowtell, Steffen Böhm, Ahmed Ahmed, Paul-Joseph Aspuria, Robert C Bast, Jr, Valerie Beral, Jonathan S Berek, Mike Birrer, Sarah Blagden, Michael A Bookman, James Brenton, Katherine B Chiappinelli, Filipe Correia Martins, George Coukos, Ronny Drapkin, Richard Edmondson, Christina Fotopoulou, Hani Gabra, Jérôme Galon, Charlie Gourley, Valerie Heong, David Huntsman, Marcin Iwanicki, Beth Karlan, Allyson Kaye, Ernst Lengyel, Douglas A Levine, Karen Lu, Iain McNeish, Usha Menon, Steve Narod, Brad H Nelson, Kenneth Nephew, Paul Pharoah, Daniel Powell, Pilar Ramos, Iris Romero, Clare Scott, Anil K Sood, Euan A Stronach, Frances Balkwill: Rethinking Ovarian Cancer II: A Roadmap for Reducing Mortality from High-grade Serous Ovarian Cancer. Nature Reviews Cancer 15(11): 668-79, Oct 2015 ...

David Bowtell, Steffen Böhm, Ahmed Ahmed, Paul-Joseph Aspuria, Robert C Bast, Jr, Valerie Beral, Jonathan S Berek, Mike Birrer, Sarah Blagden, Michael A Bookman, James Brenton, Katherine B Chiappinelli, Filipe Correia Martins, George Coukos, Ronny Drapkin, Richard Edmondson, Christina Fotopoulou, Hani Gabra, Jérôme Galon, Charlie Gourley, Valerie Heong, David Huntsman, Marcin Iwanicki, Beth Karlan, Allyson Kaye, Ernst Lengyel, Douglas A Levine, Karen Lu, Iain McNeish, Usha Menon, Steve Narod, Brad H Nelson, Kenneth Nephew, Paul Pharoah, Daniel Powell, Pilar Ramos, Iris Romero, Clare Scott, Anil K Sood, Euan A Stronach, Frances Balkwill: Rethinking Ovarian Cancer II: A Roadmap for Reducing Mortality from High-grade Serous Ovarian Cancer. Nature Reviews Cancer 15(11): 668-79, Oct 2015 ...

Purpose: In high-grade serous ovarian cancer (HGSOC), higher densities of both B cells and the CD8+ T cell infiltrate were associated with a better prognosis. However, the precise role of B cells in the anti-tumor response remains unknown. As peritoneal metastases are often responsible for relapse, our aim was to characterize the role of B cells in the anti-tumor immune response in HGSOC metastases. Experimental Design: Unmatched pre and post-chemotherapy HGSOC metastases were studied. B-cell localization was assessed by immunostaining. Their cytokines and chemokines were measured by multiplex assay and their phenotype was assessed by flow cytometry. Further in vitro and in vivo assays highlighted the role of B cells and plasma cell IgGs in the development of cytotoxic responses and dendritic cell activation. Results: B cells mainly infiltrated lymphoid structures in the stroma of HGSOC metastases. There was a strong B-cell memory response directed at a restricted repertoire of antigens and ...

PMID: 26867183, PMCID: PMC5271177. Integrated proteogenomic characterization of human high-grade serous ovarian cancer, H. Zhang, T. Liu, Z. Zhang, S. H. Payne, B. Zhang, J. E. McDermott, J. Y. Zhou, V. A. Petyuk. L. Chen, D. Ray, S. Sun, F. Yang, L. Chen, J. Wang, P. Shah, S. W. Cha, P. Aiyetan, S. Woo, Y. Tian, M. A. Gritsenko, T. R. Clauss, C. Choi, M. E. Monroe, S. Thomas, S. Nie, C. Wu, R. J. Moore, K. H. Yu, D. L. Tabb, D. Fenyo, V. Bafna, Y. Wang, H. Rodriguez, E. S. Boja, T. Hiltke, R. C. Rivers, L. Sokoll, H. Zhu, IeM. Shih, L. Cope, A. Pandey, B. Zhang, M. P. Snyder, D. A. Levine, R. D. Smith, D. W. Chan, K. D. Rodland, and CPTAC Investigators, Cell 166 (3): 755-765 (2016 ...

Ovarian-like epithelial tumors of the testis, including serous borderline tumors, are rare entities. We report the case of a 60-year-old man with a left intratesticular mass who had a radical orchidectomy. Histologically, the tumor was identical to the ovarian counterpart showing a well-delineated cystic lesion characterized by intraluminal papillae. The papillae are lined by atypical cuboidal or ciliated cells and are associated with psammoma bodies. The tumor cells express cytokeratin 7 (CK7), cytokeratin 5-6 (CK5-6), cancer antigen 125 (CA125), estrogen (ER), progesterone (PR), Wilm’s tumor gene (WT1), paired box gene 8 (PAX8), Ber-EP4, and epithelial membrane antigen (EMA). The diagnosis of a serous borderline tumor of the testis was proposed. Mutation testing using next-generation sequencing showed a Q61K KRAS gene mutation. To the best of our knowledge, this is the second case report of a serous borderline tumor of the testis with a Q61K KRAS gene mutation.

TY - JOUR. T1 - Low-grade serous carcinoma (mullerian/ovarian type) of the paratestis presenting as diffuse metastatic disease of unknown origin. T2 - Case report of an uncommon tumor with an unusual presentation. AU - Filatenkov, Alexander. AU - Strickland, Amanda. AU - Karpowicz, Matthew. AU - Francis, Franto. N1 - Publisher Copyright: © 2017 The Authors Copyright: Copyright 2017 Elsevier B.V., All rights reserved.. PY - 2018/3. Y1 - 2018/3. N2 - Low-grade (papillary) serous carcinoma of ovarian type is rare in males and histologically identical to low-grade serous carcinomas in female patients. We present a case of paratesticular low-grade serous carcinoma in a 42 year old male, with the highly unusual initial presentation as diffuse metastatic disease in the abdomen. Imaging revealed a cystic lesion of the right testis/hemiscrotum. Biopsy of the abdominal metastasis and subsequent right orchiectomy specimen showed invasive papillary serous carcinoma, low grade, with prominent psammomatous ...

TY - JOUR. T1 - Outcome after combined modality treatment for uterine papillary serous carcinoma. T2 - A study by the Rare Cancer Network (RCN). AU - Goldberg, Hadassah. AU - Miller, Robert C.. AU - Abdah-Bortnyak, Roxolyana. AU - Steiner, Mariana. AU - Yildiz, Ferah. AU - Meirovitz, Amichay. AU - Villà, Salvador. AU - Poortmans, Philip M.P.. AU - Azria, David. AU - Zidan, Jamal. AU - Ozsahin, Mahmut. AU - Abacioglu, Ufuk. AU - Gold, Douglas G.. AU - Amit, Amnon. AU - Lavie, Ofer. AU - Atahan, I. Lale. AU - Kuten, Abraham. PY - 2008/2/1. Y1 - 2008/2/1. N2 - Objectives: Uterine papillary serous carcinoma (UPSC) is a rare subtype of endometrial carcinoma, characterized by a poor outcome. We sought to better analyze the effect of surgery and adjuvant therapies on this disease. Methods: A retrospective analysis was performed on the records of 138 women diagnosed with UPSC between 1986 and 2003 in the framework of the Rare Cancer Network. Results: Median age at diagnosis was 67 years. Pure UPSC was ...

TY - JOUR. T1 - Ovarian serous cystadenofibromas associated with a low-grade serous carcinoma of the peritoneum. AU - Hinson, Stacy A.. AU - Silva, Elvio G.. AU - Pinto, K.. PY - 2013/6/1. Y1 - 2013/6/1. N2 - Ovarian serous cystadenofibromas are benign neoplasms that sometimes have focal areas of borderline serous tumor and rarely have been associated with epithelial proliferations in the peritoneum, resembling implants. We are reporting 2 cases of ovarian serous cystadenofibromas with serous peritoneal lesions of higher grade than the ovarian tumor: 1 case had a serous carcinoma and another 1 a serous borderline tumor.. AB - Ovarian serous cystadenofibromas are benign neoplasms that sometimes have focal areas of borderline serous tumor and rarely have been associated with epithelial proliferations in the peritoneum, resembling implants. We are reporting 2 cases of ovarian serous cystadenofibromas with serous peritoneal lesions of higher grade than the ovarian tumor: 1 case had a serous ...

MalaCards based summary : Cervical Serous Adenocarcinoma is related to thymus clear cell carcinoma and adult type testicular granulosa cell tumor. An important gene associated with Cervical Serous Adenocarcinoma is MLANA (Melan-A), and among its related pathways/superpathways are NF-kappaB Signaling and Primary Focal Segmental Glomerulosclerosis FSGS. Related phenotype is no phenotypic analysis ...

Uterine papillary serous carcinoma (UPSC) is an uncommon, but aggressive variant of endometrial carcinoma that has a high recurrence rate and poor response to therapy. It has a propensity to metastasize throughout the abdomen, similar to serous carcinoma of the ovary. In fact, many patients with disease apparently confined to the uterus have microscopic intra-abdominal spread at the time of diagnosis. Recurrences are common both in the pelvis as well as in the upper abdomen.. After staging and debulking of gross disease, adjuvant radiation therapy is recommended to treat patients with endometrial carcinoma at high risk for recurrent disease. High-risk features include histologic cell type, grade, depth of myometrial invasion, cervical extension, lymph-vascular invasion, adnexal involvement, intraperitoneal spread, positive peritoneal cytology, and positive lymph nodes. Pelvic radiation can limit local recurrences to less than 6.5%. However, approximately 25-30% of patients with high-risk ...

TY - JOUR. T1 - Impact of tubal ligation on routes of dissemination and overall survival in uterine serous carcinoma. AU - Ayeni, Tina A.. AU - Bakkum-Gamez, Jamie N. AU - Mariani, Andrea. AU - McGree, Michaela E.. AU - Weaver, Amy L.. AU - Alhilli, Mariam M.. AU - Martin, Janice R.. AU - Keeney, Gary. AU - Dowdy, Sean Christopher. AU - Podratz, Karl C.. PY - 2013/1. Y1 - 2013/1. N2 - Objective: Abdominal peritoneal implants are characteristic of uterine serous carcinoma (USC). The presumed mechanism of dissemination is retrograde transit via the fallopian tube. We assessed the impact of tubal ligation (TL) on the metastatic profile and survival of USC patients. Methods: Patient risk factors, process-of-care variables, and disease-specific parameters were annotated. Categorical variables were compared using the χ2 test. Overall survival (OS) was estimated via the Kaplan-Meier method. Results: Among 211 USC patients, fallopian tube status was documented in 142 patients; 35 had a history of TL ...

Objectives: To determine recurrence patterns and survival outcomes of stage II uterine papillary serous carcinoma (UPSC) patients treated by various modalities with an emphasis on carboplatin/paclitaxel-based chemotherapy (CT) +/- radiotherapy (RT). Methods: A retrospective, multi-institution study of women with stage II UPSC diagnosed from 1992 to 2006 was performed. All patients underwent comprehensive surgical staging. Treatment included observation (OBS), RT (vaginal brachytherapy, whole pelvic and/or whole abdominal therapy), or ≥ 3 cycles carboplatin/paclitaxel alone or with RT. Recurrence and survival outcomes were determined. Results: We identified 55 subjects: 10 treated with OBS, 26 with RT alone and 19 with CT +/- RT. After a median follow-up of 33 mos (range, 10-119), 20 recurrences (36%) were observed. There was an overall difference in recurrence based upon treatment (p = .013). Specifically, all CT +/- RT treated patients had a lower risk of recurrence (11%) compared to patients ...

Xu, J., et al. Mass spectrometry-based peptidome profiling of human serous ovarian cancer tissues. The International Journal of Biochemistry & Cell Biology. S1357-2725(18)30258-9. 10/12/2018.. We identified 634 differentially expressed peptides, 508 of these peptides were highly abundant in serous ovarian cancer tissues, a result consistent with higher protease activity in ovarian cancer patients. The difference in preferred cleavage sites between the serous ovarian cancer tissues and normal ovarian epithelium indicates the characteristic peptidome of ovarian cancer and the nature of cancer-associated protease activity. Interestingly, KEGG pathway analysis of the peptide precursors indicated that the differentially regulated pathways in ovarian cancer are highly consistent with the pathways discovered in other cancers. Besides, we found that a proportion of the differentially expressed peptides are similar to the known immune-regulatory peptides and anti-bacterial peptides. Then we further ...

Uterine papillary serous carcinoma: A rare type of endometrial carcinoma with worse outcomes-IJOGR-Print ISSN No:-2394-2746 Online ISSN No:-2394-2754Article DOI No:-10.18231/2394-2754.2019.0022,Indian Journal of Obstetrics and Gynecology Research-IP Innovative Publication Pvt Limited, Medical Journals Publication, Op

Journal of Oncology is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies related to breast cancer, lung cancer, gastrointestinal cancer, skin cancer, head and neck cancer, paediatric oncology, neurooncology as well as genitourinary cancer. The journal provides a multidisciplinary forum for translational and clinical oncology research in the areas of molecular pathology, genomics, diagnosis and therapy, with a specific focus on molecular targeted agents and novel immune therapies.

Researchers used Caris Molecular Intelligence® to evaluate 240 uterine papillary serous carcinoma (UPSC) and 1,587 epithelial ovarian serous carcinoma (EOC-S) samples, and to compare the molecular profiles of the two cancer subtypes.. The tumor suppressor gene TP53 was the most commonly mutated gene in both UPSC and EOC-S (76% vs. 69%) samples. UPSCs were more likely than EOC-S samples to harbor mutations in the oncogenes PIK3CA (29% vs. 2%), FBXW7 (12% vs. 1%), KRAS (9% vs. 5%), the tumor suppressor protein PTEN (7% vs. 1%), and CTNNB1 (2% vs. 0%).. Whereas uterine papillary serous carcinoma appears to have a distinct mutation profile, indicating higher activity of the PI3K/PTEN/mTOR pathway, we saw no differences between uterine papillary and ovarian serous carcinomas in alteration of the homologous recombination pathway, remarked principal investigator Robert DeBernardo, MD, Gynecologic Oncologist and Director of Minimally Invasive Surgery at the Cleveland Clinic Ob/Gyn & Womens Health ...

In this study a new low-grade serous ovarian carcinoma cell line, named as CAISMOV24, was characterized in terms of its in vitro cell growth, production of soluble biomarkers and expression of cell surface molecules. Additionally, CAISMOV24 was molecularly characterized and compared to its primary malignant cells for genomic alterations. In vitro models of well-characterized low-grade serous ovarian cell lines are currently limited in the literature. CAISMOV24 resulted from the in vitro spontaneous immortalization of primary malignant cells from ascites that was associated with a low-grade serous ovarian carcinoma. Although malignant cells of ovarian neoplasia from either tumor tissue or ascites can be cultivated in vitro for a limited period, only a minority of the primary cell cultures may become cell lines [14]. Spontaneous immortalization of primary cultures of malignant cells is an event occurring at a very low frequency. As an example, ODonnell et al. [11] reported the occurrence of only ...

TY - JOUR. T1 - Is invasive micropapillary serous carcinoma a low-grade carcinoma?. AU - Ohishi, Yoshihiro. AU - Imamura, Hiroko. AU - Aman, Murasaki. AU - Shida, Kaai. AU - Kaku, Tsunehisa. AU - Kato, Kiyoko. AU - Oda, Yoshinao. PY - 2016/1/1. Y1 - 2016/1/1. N2 - Invasive micropapillary serous carcinoma has been proposed as a synonym for low-grade serous carcinoma by some expert pathologists. In contrast, Singer and colleagues reported that some serous carcinomas with conspicuous invasive micropapillary pattern (SC-IMPs) can show high-grade nuclear atypia. However, the molecular features of such tumors have not been well documented. The aim of this study was to demonstrate and emphasize the fact that high-grade serous carcinoma confirmed by immunohistochemistry and molecular analysis can show conspicuous invasive micropapillary pattern. We selected 24 SC-IMPs and investigated: (1) their morphologic features; (2) the immunostaining pattern of p53 protein; and (3) KRAS/BRAF/TP53 gene ...

Serous borderline tumor (SBT) of the micropapillary type (SBT-MP) became one of the major pathological SBT diagnoses in addition to typical SBT, and was also defined as

Weve invested more than $4.9 billion in cancer research since 1946, all to find more - and better - treatments, uncover factors that may cause cancer, and improve cancer patients quality of life. Instead, it groups cancers into localized, regional, and distant stages: (Based on people diagnosed with endometrial cancer between 2009 and 2015. ), *SEER= Surveillance, Epidemiology, and End Results, The American Cancer Society medical and editorial content team. Due to this notion, every patient and even non-patient will not like to reach this kind of stage. For patients with FIGO Stage IA, IB, and IC UPSC who underwent complete surgical staging, the 5-year actuarial DFS by depth of myometrial invasion was 100, 71, and 40%, respectively (p = 0.006). For example, endometrioid carcinomas have a more favourable prognosis than serous adenocarcinomas. Stage: 3 Survival Rate: 30 percent. We couldnt do what we do without our volunteers and donors. Making Strides Against Breast Cancer Walks, Common ...

Epithelial ovarian cancer is a leading cause of death in gynecological cancers. While several systematic studies have revealed the mutation landscape of serous epithelial ovarian cancer, other non-serous subtypes of the disease have not been explored as extensively. Here we conduct exome sequencing of nine non-serous epithelial ovarian tumors (six endometrioid and three mucinous) and their corresponding normal DNA as well as a tumor-only granulosa cell sample. We integrated the exome data with targeted gene sequencing for 1,321 genes selected for their involvement in cancer from additional 28 non-serous ovarian tumors and compared our results to TCGA ovarian serous cystadenocarcinoma and uterine corpus endometrial carcinomas ...

I guess my hamster days steroid high is over, because I slept 10 hours last night and woke up with something similar to what Marge described, a sort of fogginess. Its not bad, but I feel like if I crawled back under the covers, I just might go back to sleep again. (Not doing that!) I agree that we are all doing so much better than any of us probably dared to hope. There are surely some rough days ahead, but one day at a time is the way to go, and making the most of each good day. I wonder if we will continue to come here after our treatments are over??? I see 20-year survivors posting here on other boards, wanting to be here as a resource to those that come after them with their same cancers. Id like to think well be like that, with this thread always flagged for email alerts, ready to jump back in when those newly diagnosed with UPSC using the SEARCH box, find this thread. Even if any of us decide to close the door on this chapter of our life and never look back, think how great it will ...

We aimed to validate the prognostic association of p16 expression in ovarian high-grade serous carcinomas (HGSC) and to explore it in other ovarian carcinoma histotypes. p16 protein expression was assessed by clinical-grade immunohistochemistry in 6525 ovarian carcinomas including 4334 HGSC using tissue microarrays from 24 studies participating in the Ovarian Tumor Tissue Analysis consortium. p16 expression patterns were interpreted as abnormal (either overexpression referred to as block expression or absence) or normal (heterogeneous). CDKN2A (which encodes p16) mRNA expression was also analyzed in a subset (n = 2280) mostly representing HGSC (n = 2010). Association of p16 expression with overall survival (OS) was determined within histotypes as was CDKN2A expression for HGSC only. p16 block expression was most frequent in HGSC (56%) but neither protein nor mRNA expression was associated with OS. However, relative to heterogeneous expression, block expression was associated with shorter OS in

Zanotti The Cleveland Clinic Foundation Uterine papillary serous carcinoma (UPSC) is undoubtedly an intense malignancy which has a histologic visual appeal and pattern of spread that resembles that of papillary serous adenocarcinoma with the ovary. The current conventional therapy for Superior ovarian most cancers, cisplatin or carboplatin moreover paclitaxel, results in high aim response premiums for that tumor. This program has Up to now not been evaluated in i thought about this UPSC. Approaches: 20-four sufferers with UPSC treated with platinum-based mostly chemotherapy and paclitaxel were being retrospectively evaluated. Eighteen clients acquired these agents within the adjuvant placing (n = 9) or for sickness persistent just after initial surgical management (n = nine). Eleven patients gained one or more classes of this drug blend for recurrent ailment, 5 of whom experienced prior publicity while in the First setting ...

Mutations in BRCA1 or BRCA2 (BRCA) are common in patients with high-grade serous ovarian carcinomas, and, when the wild-type allele is lost, BRCA mutations can impair DNA-damage repair by homologous recombination, leading to deletion or duplication of chromosomal regions, which is termed genomic loss of heterozygosity (LOH). Homologous recombination-deficient tumors are sensitive to PARP inhibitors such as rucaparib, but although homologous recombination deficiencies can also occur in ovarian tumors without BRCA mutations, molecular predictors of rucaparib sensitivity in BRCA wild-type tumors have not been identified. Swisher, Lin, and colleagues hypothesized that genomic LOH might predict homologous recombination deficiency and rucaparib sensitivity and enrolled 206 patients in an open-label phase II trial of rucaparib in patients with relapsed, platinum-sensitive, high-grade ovarian carcinoma. In total, 192 patients could be classified into subgroups: 40 had BRCA mutations, 82 were BRCA ...

Ueda SM, Yap, KL, Davidson, B et al. Expression of fatty acid synthase depends on NAC1 and is associated with recurrent ovarian serous carcinomas. J Oncology 2010;2010:285191.. Krill LS, Ueda SM, Gerardi M, Bristow RE. Analysis of postoperative complications associated with the use of anti-adhesion sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier after cytoreductive surgery for ovarian, fallopian tube and peritoneal cancers. Article in press for Gynecol Oncol. 2011 Feb; 120(2):220-3. Skaznik-Wikiel ME, Ueda SM, Frasure HE, Rose PG, Fleury A, Grumbine FC, Nickles-Fader A. Abnormal cervical cytology in the diagnosis of uterine papillary serous carcinoma: earlier detection of a poor prognostic cancer subtype? Acta Cytol 2001;55(3):255-60.. Bristow RE, Ueda S, Gerardi MA, Ajiboye OB, Ibeanu OA. Analysis of racial disparities in stage IIIC epithelial ovarian cancer care and outcomes in a tertiary gynecologic oncology referral center. Gynecol Oncol 2011;122(2):319-23.. Giuntoli RL, Gerardi ...

Cancer cell lines have been, and will continue to be, important tools in oncology research, but there are major limitations in the fidelity of existing cell lines as a model of human cancers. Therefore, the aim of our study was to generate and characterize patient-specific cell lines from solid tumors that more faithfully recapitulate the primary tumor genetic and morphologic characteristics.. We performed cell line derivation on a primary human breast adenocarcinoma (ER+/PR+/HER2-), a lung adenocarcinoma, a high-grade serous ovarian carcinoma, and an endometrioid ovarian carcinoma procured from a commercial tissue bank. Portions were snap-frozen for molecular analysis, and the remainder was minced and processed for cell culture. Cells were cultured and the resulting monolayer was stained by immunocytochemistry with a pan-keratin antibody for the presence of epithelial cells. Any contaminating fibroblasts were removed. We extracted DNA from the resulting breast and lung cancer cell lines at low, ...

4. Mills AM, Peres LC, Meiss A, Ring KL, Modesitt SC, Abbott SE, Alberg AJ, Bandera EV, Barnholtz-Sloan J, Bondy ML, Cote ML, Funkhouser E, Moorman PG, Peters ES, Schwartz AG, Terry PD, Wallace K, Schildkraut JM. Targetable immune regulatory molecule expression in high-grade serous ovarian carcinomas in African American women: A study of PD-L1 and IDO in 112 cases from the African American Cancer Epidemiology Study (AACES). Int J Gynecol Pathol. 2018 Feb 26 [Epub ahead of print]. IF: 1.5 Role: Subject recruitment, data analysis, manuscript preparation. 5. Holowatyj AN*, Cote ML, Ruterbusch JJ, Ghanem K, Schwartz AG, Vigneau FD, Gorski DH, Purrington KS. Racial differences in 21-Gene recurrence scores among patients with hormone receptor-positive, node-negative breast cancer. J Clin Oncol. 2018 Mar 1; 36(7):652-658. IF: 24.0. 6. Peres LC, Risch H, Terry KL, Webb PM, Goodman MT, Wu AH, Alberg AJ, Bandera EV, Barnholtz-Sloan J, Bondy ML, Cote ML, Funkhouser E, Moorman PG, Peters ES, Schwartz AG, ...

Faculty contributors to the definition and algorithm:. Drs. R. Vang, R.J. Kurman, K. Visvanathan, P. Shaw, R. Soslow, V. Parkash, and I. Shih. The intention of the information provided in this web site is at present for educational and research purposes only. The biological and clinical significance of STIC and STIL is a work in progress and their impact to clinical management has still to be defined. The investigators involved in this study and all the web pages in ovariancancerprevention.org do not recommend the use of this pathological and immunostaining classification for clinical practice at the present time. Ovarian high-grade serous carcinoma (HGSC) is the most lethal gynecologic malignancy and is characterized by frequent TP53 mutations and a high level of chromosomal instability, which is reflected by widespread DNA copy number changes compared to other types of epithelial ovarian carcinomas. Unlike cancers arising in the colon, breast, cervix, endometrium, prostate, and pancreas, for ...

TY - JOUR. T1 - Augmentation of Response to Chemotherapy by microRNA-506 Through Regulation of RAD51 in Serous Ovarian Cancers. AU - Liu, Guoyan. AU - Yang, Da. AU - Rupaimoole, Rajesha. AU - Pecot, Chad V.. AU - Sun, Yan. AU - Mangala, Lingegowda S.. AU - Li, Xia. AU - Ji, Ping. AU - Cogdell, David. AU - Hu, Limei. AU - Wang, Yingmei. AU - Rodriguez-Aguayo, Cristian. AU - Lopez-Berestein, Gabriel. AU - Shmulevich, Ilya. AU - De Cecco, Loris. AU - Chen, Kexin. AU - Mezzanzanica, Delia. AU - Xue, Fengxia. AU - Sood, Anil K.. AU - Zhang, Wei. N1 - Publisher Copyright: © 2015 The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: [email protected].. PY - 2015/7/1. Y1 - 2015/7/1. N2 - Background: Chemoresistance is a major challenge in cancer treatment. miR-506 is a potent inhibitor of the epithelial-to-mesenchymal transition (EMT), which is also associated with chemoresistance. We characterized the role of miR-506 in chemotherapy ...

Author(s): Hu, Ye; Taylor-Harding, Barbie; Raz, Yael; Haro, Marcela; Recouvreux, Maria Sol; Taylan, Enes; Lester, Jenny; Millstein, Joshua; Walts, Ann E; Karlan, Beth Y; Orsulic, Sandra | Abstract: Primary ovarian high-grade serous carcinoma (HGSC) has been classified into 4 molecular subtypes: Immunoreactive, Proliferative, Differentiated, and Mesenchymal (Mes), of which the Mes subtype (Mes-HGSC) is associated with the worst clinical outcomes. We propose that Mes-HGSC comprise clusters of cancer and associated stromal cells that detached from tumors in the upper abdomen/omentum and disseminated in the peritoneal cavity, including to the ovary. Using comparative analyses of multiple transcriptomic data sets, we provide the following evidence that the phenotype of Mes-HGSC matches the phenotype of tumors in the upper abdomen/omentum: (1) irrespective of the primary ovarian HGSC molecular subtype, matched upper abdominal/omental metastases were typically of the Mes subtype, (2) the Mes subtype was

of the uterus, adenexae, onsectonomy and appendectomy for papillary serous carcinoma of the ovary . After 6 chemotherapy cycles tumor recurrence .... ...

Bouchalova, P., Nenutil, R., Muller, P., Hrstka, R., Appleyard, M. V., Murray, K., Jordan, L. B., Purdie, C. A., Quinlan, P., Thompson, A. M., Vojtesek, B. & Coates, P. J. Jul 2014 In : Journal of Pathology. 233, 3, p. 238-246 9 p.. Research output: Contribution to journal › Article ...

Patients with ovarian high-grade serous carcinoma (HGSC) initially respond to treatment with the chemotherapeutic agents carboplatin and paclitaxel, but frequently experience tumor relapse. However, the mechanisms underlying the development of resistance to these drugs remain poorly understood. Yu and colleagues found that the levels of spleen tyrosine kinase (SYK) and phosphorylated SYK were increased in recurrent ovarian tumors isolated from patients previously treated with carboplatin and paclitaxel compared with matched primary untreated tumors. In addition, SYK expression and activation were upregulated in paclitaxel-resistant ovarian cancer cell lines and positively correlated with paclitaxel response in vitro, suggesting that SYK overexpression may confer chemoresistance. SYK inactivation via knockdown or pharmacologic inhibition with the active metabolite of fostamatinib, R406, impaired the growth of ovarian cancer cells and synergistically enhanced the sensitivity of ...

The present review showed that IRT alone may be an adequate RT technique in women with stage I USC, who underwent appropriate surgical staging and received adjuvant chemotherapy.. Uterine serous carcinoma patients have a high-risk to develop local and distant relapse [28], therefore it is essential to ensure an adequate treatment even if patients with an early stage disease. While prospective studies have demonstrated that the delivery of chemotherapy in combination with external beam radiation in an advanced stage disease may increase survival benefit and decreases local recurrences [29,30,31,32,33], the role of radiation in early stage USC has been more difficult to demonstrate.. Owing to high-rate of distant recurrences, many studies recommended a more systemic approach to therapy for USC [34]. Treatment of women with uterine-confined USC with adjuvant chemotherapy is controversial due to lack of prospective randomized trials. However, in patients with stage I/II disease who were treated with ...

Journal of Clinical and Diagnostic Research aims to publish findings of doctors at grass root level and post graduate students, so that all unique medical experiences are recorded in literature.

Brain Development The shaky pattern continues to knowledgeable everywhere early, and the developing in ceo circumference is indicative of wit growth. Shifting Responsibilities From Hospital-Based to Community-Based Nursing Care Over the sometime century changes in vigorousness attention, such as uncomfortable salubrity care funding, shorter asylum stays, and sell for containment, include led to a make it in responsibilities of care payment children from the infirmary to homes and communities. Chemic toxins are each approximately you in cleansing supplies, pesticides, herbicides, and matter additives generic 30 gm himcolin with mastercard natural erectile dysfunction treatment remedies. Patterns of p53 mutations partition ovarian serous borderline tumors and low- and high-grade carcinomas and provide keep proper for a new prototype of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Non-critical stimulation coupled effects (viscerosensory symptoms, cough, ...

PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.

One subtype of breast cancer shares many genetic features with high-grade serous ovarian cancer, a cancer that is very difficult to treat, according to researchers supported by the National Institutes of Health. The findings suggest that the two cancers are of similar molecular origin, which may facilitate the comparison of therapeutic data for subtypes of breast and ovarian cancers.

Decreased Expression of 14-3-3,i,σ,/i, Is Predictive of Poor Prognosis for Patients with Human Uterine Papillary Serous Carcinoma （2013 ...

The biology of ovarian carcinoma differs from that of hematogenously metastasizing tumors because ovarian cancer cells primarily disseminate within the peritoneal cavity and are only superficially invasive. However, since the rapidly proliferating tumors compress visceral organs and are only temporarily chemosensitive, ovarian carcinoma is a deadly disease, with a cure rate of only 30%. There are a number of genetic and epigenetic changes that lead to ovarian carcinoma cell transformation. Ovarian carcinoma could originate from any of three potential sites: the surfaces of the ovary, the fallopian tube, or the mesothelium-lined peritoneal cavity. Ovarian cacinoma tumorigenesis then either progresses along a stepwise mutation process from a slow growing borderline tumor to a well-differentiated carcinoma (type I) or involves a genetically unstable high-grade serous carcinoma that metastasizes rapidly (type II). During initial tumorigenesis, ovarian carcinoma cells undergo an ...

A Study Combining the Peposertib (M3814) Pill with Standard Chemotherapy in Patients with Ovarian Cancer with an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer - NCT04092270

Siddhartha P. Kar, Jonathan P. Tyrer, Qiyuan Li, Kate Lawrenson, Katja K.H. Aben, Hoda Anton-Culver, Natalia Antonenkova, Georgia Chenevix-Trench, ; on behalf of the Australian Cancer Study, ; and on behalf of the Australian Ovarian Cancer Study Group, Helen Baker, Elisa V. Bandera, Yukie T. Bean, Matthias W. Beckmann, Andrew Berchuck, Maria Bisogna, Line Bjørge, Natalia Bogdanova, Louise Brinton, Angela Brooks-Wilson, Ralf Butzow, Ian Campbell, Karen Carty, Jenny Chang-Claude, Yian Ann Chen, Zhihua Chen, Linda S. Cook, Daniel Cramer, Julie M. Cunningham, Cezary Cybulski, Agnieszka Dansonka-Mieszkowska, Joe Dennis, Ed Dicks, Jennifer A. Doherty, Thilo Dörk, Andreas du Bois, Matthias Dürst, Diana Eccles, Douglas F. Easton, Robert P. Edwards, Arif B. Ekici, Peter A. Fasching, Brooke L. Fridley, Yu-Tang Gao, Aleksandra Gentry-Maharaj, Graham G. Giles, Rosalind Glasspool, Ellen L. Goode, Marc T. Goodman, Jacek Grownwald, Patricia Harrington, Philipp Harter, Alexander Hein, Florian Heitz, Michelle ...

My name is Shirley Pattan, I live in Jacksonville, Florida with my spouse, two (of five!) kids, and three fur babies. I was diagnosed at 40 July 2017 with stage 3c high grade serous ovarian cancer, which prompted testing for the BRCA mutation.

Atıf İçin Kopyala Unal I., Khiavi I., Tasar G., Goksuluk D. , Boyraz G., Ozgul N., ...Daha Fazla Biotechnic & histochemistry : official publication of the Biological Stain Commission, ss.1-10, 2019 (SCI İndekslerine Giren Dergi) ...